EyeGene,Inc Logo

EyeGene,Inc

Develops gene/cell therapies for age-related diseases and preventive vaccines.

185490 | KO

Overview

Corporate Details

ISIN(s):
KR7185490000
LEI:
Country:
South Korea
Address:
경기도 의왕시 양지편2로 13 2층, 의왕시

Description

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-29 00:00
투자판단관련주요경영사항 (대상포진 백신 EGHZ 국내 기술이전 계약 해지 및 권리 정리)
Korean HTML 6.1 KB
2025-12-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 28.6 KB
2025-12-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 29.4 KB
2025-12-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.5 KB
2025-12-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.6 KB
2025-12-17 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 152.5 KB
2025-12-17 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.5 KB
2025-12-17 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 26.5 KB
2025-12-17 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.5 KB
2025-09-17 00:00
증권신고서(지분증권) (2025.11)
Korean HTML 1.8 MB
2025-09-16 00:00
주요사항보고서(유상증자결정)
Korean HTML 32.6 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean HTML 1.1 MB
2025-06-30 00:00
투자판단관련주요경영사항(임상시험계획승인신청등결정) (4가 수막구균 접합백신 ‘EGMCV4의 국내 임상 제2/3상 임상시…
Korean HTML 17.9 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean HTML 1.1 MB
2025-05-12 00:00
주식매수선택권부여에관한신고
Korean HTML 18.1 KB

Automate Your Workflow. Get a real-time feed of all EyeGene,Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for EyeGene,Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for EyeGene,Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.